Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 14/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10161766 | 0.81 | ALOX5AP (0.37) | ALOX5APMAPTLMNAJAK2MAP4K4 | |
| SCHEMBL10161795 | 0.75 | MAPT (0.43) | ALOX5APMAPTLMNAFEN1MAP4K4 | |
| SCHEMBL10161770 | 0.72 | ALOX5AP (0.41) | ALOX5APMAPTLMNAFEN1MAP4K4 | |
| SCHEMBL669324 | 0.70 | ALOX5AP (0.46) | ALOX5APMAPTLMNAFEN1JAK2 | |
| SCHEMBL10160597 | 0.70 | ALOX5AP (0.46) | ALOX5APMAPTLMNAFEN1JAK2 | |
| SCHEMBL10160734 | 0.70 | MAPT (0.44) | ALOX5APMAPTLMNAFEN1MAP4K4 | |
| SCHEMBL12869440 | 0.69 | MAPT (0.47) | ALOX5APMAPTLMNAMAP4K4EGFR | |
| SCHEMBL12019806 | 0.69 | MAPT (0.38) | ALOX5APMAPTLMNAFEN1MAP4K4 | |
| SCHEMBL10161797 | 0.68 | MAPT (0.43) | ALOX5APMAPTLMNAFEN1MAP4K4 | |
| SCHEMBL10161777 | 0.66 | ALOX5AP (0.43) | ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2809321-B1 | PHENYL-C-OXADIAZOLE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE PRODUCTION FOR USE IN COMBINATION THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2016-11-09 | — | — | EP | disclosed |
| US-9248187-B2 | Oxadiazole inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| US-9248187-B2 | Oxadiazole inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| EP-2606045-B1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2016-01-06 | — | — | EP | disclosed |
| WO-2013113799-A1 | PHENYL -C-OXADIAZOLE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE PRODUCTION COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | WO | disclosed |
| US-20130195879-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| WO-2012024150-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | ALOX5AP 17/4885MAPT 4668/4885LMNA 1745/4885 |
| US-20130195879-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | LTB4R, LTB4R2, LTC4S | ALOX5AP 24/4885MAPT 4716/4885LMNA 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.